Xilio Therapeutics, Inc.
XLO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $121,439 | $65,575 | $54,113 | $61,766 |
| - Cash | $103,764 | $121,551 | $89,073 | $55,291 |
| + Debt | $7,263 | $7,566 | $7,864 | $8,142 |
| Enterprise Value | $24,938 | -$48,410 | -$27,096 | $14,617 |
| Revenue | $19,066 | $8,084 | $2,930 | $1,724 |
| % Growth | 135.8% | 175.9% | 70% | – |
| Gross Profit | $18,726 | -$7,246 | $2,930 | $1,724 |
| % Margin | 98.2% | -89.6% | 100% | 100% |
| EBITDA | -$15,947 | -$13,985 | -$13,354 | -$13,254 |
| % Margin | -83.6% | -173% | -455.8% | -768.8% |
| Net Income | -$16,287 | -$15,844 | -$13,265 | -$13,093 |
| % Margin | -85.4% | -196% | -452.7% | -759.5% |
| EPS Diluted | -0.11 | -0.16 | -0.18 | -0.2 |
| % Growth | 31.3% | 11.1% | 10% | – |
| Operating Cash Flow | -$17,495 | -$14,477 | $28,978 | -$14,157 |
| Capital Expenditures | $0 | -$401 | -$22 | -$6 |
| Free Cash Flow | -$17,495 | -$14,878 | $28,956 | -$14,163 |